ResearcherTaipei Medical UniversityActive in the last 2 years
Shiow‐Lin Pan
Matched on ORCID iD 0000-0001-7449-3539; OpenAlex author ID A5075967549. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 11
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers
Papers 7
- Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure-Based Virtual Screening. Co-author DOI 10.1002/advs.202416323↗
- Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer. Co-author DOI 10.1080/14756366.2025.2538673↗
- Discovery of novel TANK-Binding Kinase 1 (TBK1) inhibitor against pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ijbiomac.2024.137296↗
- An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. Co-author DOI 10.1016/j.bbrc.2023.149214↗
- In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer. Last author DOI 10.1080/14756366.2023.2166039↗
- Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Last author DOI 10.1186/s13148-019-0681-6↗
- Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis. First author DOI 10.1016/j.ajpath.2013.04.022↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kai‐Cheng Hsu · 4 shared papers, 2023–2025 · strength 0.88
- Paper Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer. DOI 10.1080/14756366.2025.2538673↗
- Paper Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer … DOI 10.1002/advs.202416323↗
- Paper Discovery of novel TANK-Binding Kinase 1 (TBK1) inhibitor against pancreatic ductal adenocarcinoma. DOI 10.1016/j.ijbiomac.2024.137296↗
- Min‐Wu Chao · 3 shared papers, 2019–2025 · strength 0.57
- Paper Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer. DOI 10.1080/14756366.2025.2538673↗
- Paper In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer. DOI 10.1080/14756366.2023.2166039↗
- Paper Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor b… DOI 10.1186/s13148-019-0681-6↗
- Chi-Hsiu Chung · 1 shared paper, 2025 · strength 0.30
- Chao-Di Chang · 2 shared papers, 2019–2023 · strength 0.26
- Paper In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer. DOI 10.1080/14756366.2023.2166039↗
- Paper Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor b… DOI 10.1186/s13148-019-0681-6↗
- Chun-Lin Yang · 1 shared paper, 2025 · strength 0.22
- Yi-Wen Wu · 1 shared paper, 2025 · strength 0.22
- Fu-Ling Chang · 1 shared paper, 2023 · strength 0.20
- Yu‐Ching Lee · 1 shared paper, 2023 · strength 0.20
- Wan-Hsi Shih · 1 shared paper, 2024 · strength 0.20
- Li-Hsun Chang · 2 shared papers, 2013–2019 · strength 0.14
- Paper Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor b… DOI 10.1186/s13148-019-0681-6↗
- Paper Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-media… DOI 10.1016/j.ajpath.2013.04.022↗
- Che‐Ming Teng · 2 shared papers, 2013–2019 · strength 0.14
- Paper Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor b… DOI 10.1186/s13148-019-0681-6↗
- Paper Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-media… DOI 10.1016/j.ajpath.2013.04.022↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.